Long Non-Coding RNA H19 Expression and Functional Polymorphism rs217727 Are Linked to Increased Ischemic Stroke Risk

Rezaei, Mohadese; Mokhtari, Mohammad Javad; Bayat, Mahnaz; Safari, Anahid; Dianatpuor, Mehdi; Borhani-Haghighi, Afshin

doi:10.21203/rs.3.rs-104420/v1

Cited by 4 publications

(4 citation statements)

References 36 publications

(58 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There has been evidence that H19 has a significant effect on the onset, development, and progression stages of atherosclerosis [24] . A study in an Iranian population found that circulating levels of H19 within 24 h of ischemic stroke onset could be used as an early diagnostic biomarker [25] . Wang et al [26] found that peripheral blood mononuclear cell-derived H19 was a risk factor for acute myocardial infarction and had significant diagnostic value.…”

Section: Discussionmentioning

confidence: 99%

Role of circulating long non-coding RNA for the improvement of the predictive ability of the CHA2DS2–VASc score in patients with atrial fibrillation

Zhang

Chen

et al. 2022

Chinese Medical Journal

View full text Add to dashboard Cite

Background: The CHA 2 DS 2 –VASc score was initially applied to stratify stroke risk in patients with atrial fibrillation (AF) and was found to be effective in predicting all-cause mortality outcomes. To date, it is still unclear whether circulating long non-coding RNAs (lncRNAs) as emerging biomarkers, can improve the predictive power of the CHA 2 DS 2 –VASc score in stroke and all-cause mortality. Methods: Candidate lncRNAs were screened by searching the literature and analyzing previous RNA sequencing results. After preliminary verification in 29 patients with AF, the final selected lncRNAs were evaluated by Cox proportional hazards regression in 192 patients to determine whether their relative expression levels were associated with stroke and all-cause mortality. The c-statistic, net reclassification improvement (NRI), and integrated discrimination improvement of the patients were calculated to evaluate the discrimination and reclassification power for stroke and all-cause mortality when adding lncRNA expression levels to the CHA 2 DS 2 –VASc score model. Results: Five plasma lncRNAs associated with stroke and all-cause mortality in AF patients were selected in our screening process. Patients with elevated H19 levels were found to have a higher risk of stroke (hazard ratio [HR] 3.264, 95% confidence interval [CI]: 1.364–7.813, P = 0.008). Adding the H19 expression level to the CHA 2 DS 2 –VASc score significantly improved the discrimination and reclassification power of the CHA 2 DS 2 –VASc score for stroke in AF patients. In addition, the H19 level showed a marginally significant association with all-cause mortality (HR 2.263, 95% CI: 0.889–5.760, P = 0.087), although it appeared to have no significant improvement for the CHA 2 DS 2 –VASc model for predicting all-cause mortality. Conclusions: Plasma expression of H19 was associated with stroke risk in AF patients and improved the discriminatory power of the CHA 2 DS 2 –VASc score. Therefore, lncRNA H19 served as an emerging non-invasive biomarker for stroke risk prediction in patients with AF.

show abstract

Section: Discussionmentioning

confidence: 99%

Role of circulating long non-coding RNA for the improvement of the predictive ability of the CHA2DS2–VASc score in patients with atrial fibrillation

Zhang

Chen

et al. 2022

Chinese Medical Journal

View full text Add to dashboard Cite

show abstract

“…118 Interestingly, in stroke patients, H19 was increased in the leukocytes, blood, and serum and circulating H19 levels were associated with increased risk for ischemic stroke. 110,112,116,119–122 This indicates the potential of H19 to serve as a biomarker for the prognosis for ischemic stroke.…”

Section: Epigenetic Mechanisms In Strokementioning

confidence: 95%

Epigenetic mechanisms and potential therapeutic targets in stroke

Morris-Blanco

Chokkalla

Arruri

et al. 2022

J Cereb Blood Flow Metab

View full text Add to dashboard Cite

Accumulating evidence indicates a central role for epigenetic modifications in the progression of stroke pathology. These epigenetic mechanisms are involved in complex and dynamic processes that modulate post-stroke gene expression, cellular injury response, motor function, and cognitive ability. Despite decades of research, stroke continues to be classified as a leading cause of death and disability worldwide with limited clinical interventions. Thus, technological advances in the field of epigenetics may provide innovative targets to develop new stroke therapies. This review presents the evidence on the impact of epigenomic readers, writers, and erasers in both ischemic and hemorrhagic stroke pathophysiology. We specifically explore the role of DNA methylation, DNA hydroxymethylation, histone modifications, and epigenomic regulation by long non-coding RNAs in modulating gene expression and functional outcome after stroke. Furthermore, we highlight promising pharmacological approaches and biomarkers in relation to epigenetics for translational therapeutic applications.

show abstract

“…In vitro, H19 targeted HDAC1 to inhibit the polarization of microglial M2 phenotype and promote neuroinflammation. (Jaworska et al, 2017;Rezaei et al, 2021;Wang et al, 2017a) Gu et al found that H19 expression was up-regulated in the spinal cord injury model compared with control mice. Up-regulation of H19 expression could promote apoptosis and inflammation of BV2 cells.…”

Section: H19mentioning

confidence: 99%

The Common LncRNAs of Neuroinflammation-Related Diseases

et al. 2022

View full text Add to dashboard Cite

Spatio-temporal specific lncRNAs play important regulatory roles not only in the growth and development of the brain but also in the occurrence and development of neurological diseases. Generally, the occurrence of neurological diseases is accompanied by neuroinflammation. Elucidation of the regulatory mechanisms of lncRNAs on neuroinflammation is helpful for the clinical treatment of neurological diseases. This paper focuses on recent findings on the regulatory effect of lncRNAs on neuroinflammatory diseases and selects ten lncRNAs that have been intensively studied to analyze their mechanism of action.The clinical treatment status of lncRNAs as drug targets is also reviewed. Significance StatementGene therapies such as CRISPR/Cas9 technology, antisense RNA technology and RNAi technology are gradually applied in clinical treatment, and the development of technology is based on a large number of basic research investigations. This paper focuses on the mechanisms of lncRNAs regulation of neuroinflammation, elucidates the beneficial or harmful effects of lncRNAs in neurosystemic diseases, and provides theoretical bases for lncRNAs as drug targets.

show abstract

Long Non-Coding RNA H19 Expression and Functional Polymorphism rs217727 Are Linked to Increased Ischemic Stroke Risk

Cited by 4 publications

References 36 publications

Role of circulating long non-coding RNA for the improvement of the predictive ability of the CHA2DS2–VASc score in patients with atrial fibrillation

Role of circulating long non-coding RNA for the improvement of the predictive ability of the CHA2DS2–VASc score in patients with atrial fibrillation

Epigenetic mechanisms and potential therapeutic targets in stroke

The Common LncRNAs of Neuroinflammation-Related Diseases

Contact Info

Product

Resources

About